NOVEMBER 2023LIFE SCIENCES REVIEW8IN MY OPINIONUNVEILING INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT Anthony Mack is a driving force behind the success and triumphs at Virpax Pharmaceuticals, skillfully engaging in diverse activities that significantly contribute to the company's achievements. Leading regulatory meetings, he navigates intricate product development processes, involving formulation and preclinical research. His strategic prowess shines in securing non-dilutive funding. Collaborating with grant writers, Mack ensures precise grant submissions to esteemed institutions like the NIH and the DoD, while maintaining impeccable compliance standards. His influence extends to liaising with investment banks, vital for licensing assets globally. Partnerships in Europe and China secure upfront fees, milestones, and royalties, aligning with the company's US market focus. Mack's journey spans roles from sales to co-founding ProSolus, culminating in a successful acquisition. His weekly agenda encompasses dynamic regulatory negotiations, grant strategies, investment collaborations, and a focused US market approach, epitomizing his background and aspirations in driving Virpax's continued success.In an interview with Pharma Tech Outlook magazine, Mack shares his insights on the challenges and emerging trends in the pharma consulting industry and the experience he has gathered in the domain.What, are some of the major priorities, and hurdles, that you are currently managing in this role?As a development stage company, we have a lot on our plate. We are currently focused on securing assets through licensing agreements, specifically at the preclinical stage. Our top priority is to refine the formulation to meet our optimal standards. We are unwavering in our commitment to achieving a robust formulation before advancing to the clinical phase. This strategic approach is non-negotiable for every asset we bring on board.Once we attain this critical formulation milestone, our immediate objective shifts to our current phase of progress. This entails navigating through the preclinical stage with utmost diligence.We focus on conducting thorough animal studies, strategically aligning with regulatory requirements, and engaging proficient Contract Research Organizations (CROs). We are determined to comprehensively fulfill all FDA prerequisites, propelling us toward the subsequent phase. Our projected timeline is clear-cut: We are gearing up for human trials, an endeavor we anticipate initiating in 2024. As the Chairman and CEO, how do you effectively implement a range of strategies in the multidisciplinary field of pain management and ensure that these strategies are closely aligned with your organization's objectives?Our company is dedicated to By Anthony P Mack, Founding Chairman and CEO, Viprax Pharmaceuticals
< Page 7 | Page 9 >